II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931535, encodeId=03e81931535b6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=78, createdTime=2021-01-27, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931525, encodeId=cc6e19315259f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, objectType=article, longId=200046, objectId=dd8a2000461b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8a2000461b, replyNumber=0, likeNumber=64, createdTime=2020-09-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8a2000461b, moduleTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8a2000461b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931514, encodeId=ec89193151459, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, objectType=article, longId=195935, objectId=1c30195935d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c30195935d4, replyNumber=0, likeNumber=90, createdTime=2021-02-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c30195935d4, moduleTitle=关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c30195935d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931551, encodeId=3c63193155124, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, objectType=article, longId=207256, objectId=1d0f20e25662, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0f20e25662, replyNumber=0, likeNumber=32, createdTime=2021-03-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0f20e25662, moduleTitle=NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0f20e25662)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931528, encodeId=82cf19315286f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=80, createdTime=2021-08-27, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931509, encodeId=a67b193150906, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=81, createdTime=2020-11-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931504, encodeId=b3fd193150447, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=86, createdTime=2020-07-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931532, encodeId=b10c1931532ee, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , objectType=article, longId=201778, objectId=df60201e785f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df60201e785f, replyNumber=0, likeNumber=69, createdTime=2021-07-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df60201e785f, moduleTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df60201e785f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931527, encodeId=bef8193152e7a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=62, createdTime=2021-02-05, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931505, encodeId=6ea71931505b1, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=51, createdTime=2021-03-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931497, encodeId=2996193149e98, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=61, createdTime=2020-11-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931515, encodeId=c7a41931515b8, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, objectType=article, longId=196105, objectId=041919610548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=041919610548, replyNumber=0, likeNumber=70, createdTime=2020-12-05, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=041919610548, moduleTitle=III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=041919610548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931510, encodeId=14d7193151074, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, objectType=article, longId=194057, objectId=3dae19405ec5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dae19405ec5, replyNumber=0, likeNumber=77, createdTime=2021-03-21, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dae19405ec5, moduleTitle=学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dae19405ec5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931520, encodeId=5307193152017, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, objectType=article, longId=198175, objectId=65311981e586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65311981e586, replyNumber=0, likeNumber=0, createdTime=2020-12-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65311981e586, moduleTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65311981e586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931517, encodeId=24bc193151ea2, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=57, createdTime=2020-09-06, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931539, encodeId=87a1193153977, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, objectType=article, longId=203249, objectId=a99020324958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a99020324958, replyNumber=0, likeNumber=74, createdTime=2021-02-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a99020324958, moduleTitle=北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a99020324958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931544, encodeId=61d61931544a4, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, objectType=article, longId=204701, objectId=9ebf204e014c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ebf204e014c, replyNumber=0, likeNumber=49, createdTime=2021-05-06, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ebf204e014c, moduleTitle=Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ebf204e014c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931533, encodeId=58b4193153371, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=单抗III期临床试验失败案例及原因分析, objectType=article, longId=201985, objectId=5e8f20198506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8f20198506, replyNumber=0, likeNumber=93, createdTime=2021-04-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8f20198506, moduleTitle=单抗III期临床试验失败案例及原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e8f20198506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931531, encodeId=f7511931531e3, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=85, createdTime=2021-07-24, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931492, encodeId=7d29193149219, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, objectType=article, longId=187514, objectId=65e518e5149c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e518e5149c, replyNumber=0, likeNumber=57, createdTime=2020-09-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e518e5149c, moduleTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e518e5149c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2021-01-27

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验

2020-09-07

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

关注罕见病“红细胞生成性原卟啉症及X连锁卟啉症”：已启动MT-7117全球III期临床试验

2021-02-18

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

NEJM：每日一次Relugolix联合疗法治疗子宫肌瘤的III期临床试验

2021-03-17

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验

2021-08-27

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-11-09

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2020-07-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？

2021-07-30

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2021-02-05

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2021-03-08

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-11-11

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验证明：Dorzagliatin单药治疗2型糖尿病疗效确切

2020-12-05

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

学术前沿| 天津总医院杨学军团队发现原研新药ACT001抑制胶质瘤生长新机制 II期临床试验将启动

2021-03-21

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组

2020-12-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2020-09-06

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

北京科兴生物的新冠COVID-19疫苗在巴西的III期临床试验被暂停

2021-02-19

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Mithra宣布Donesta治疗更年期血管舒缩症状（VMS）的III期临床试验已取得积极结果

2021-05-06

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

单抗III期临床试验失败案例及原因分析

2021-04-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2021-07-24

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验

2020-09-14

科室
- - 订阅+
  - 更多科室
工具
服务